Clareo Health | Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allogene Therapeutics
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histological or cytological diagnosis of Large B-cell Lymphoma (LBCL) or Follicular Lymphoma.
Relapse or refractory disease after at least 2 lines of chemotherapy
At least 1 measurable lesion at time of screening.
Eastern Cooperative Oncology Group Performance Status of 0 or 1.
Adequate hematological, renal, liver, pulmonary, and cardiac functions.
You may not be if
Current or history of central nervous system (CNS) lymphoma.
Clinically significant CNS dysfunction.
ASCT within last 6 weeks or allogeneic HSCT within last 3 months prior to ALLO-647.
Prior treatment with anti-CD19 therapy, any gene therapy, any genetically modified cell therapy or adoptive T cell therapy
Systemic anticancer therapy within 2 weeks prior to study entry.
On-going treatment with immunosuppressive agents.
Active acute or chronic graft versus host disease (GvHD), or GvHD requiring immunosuppressive treatment within 4 weeks of enrollment.
Any form of primary or acquired immunodeficiency (e.g., severe combined immunodeficiency disease).
Current thyroid disorder (including hyperthyroidism), except for subjects with hypothyroidism controlled on a stable dose of hormone replacement therapy.
Patients unwilling to participate in an extended safety monitoring period
